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In post-stroke patients, the recurrence of stroke and progression of impairments lead to a bedridden state and dementia. As for
their treatments, only anti-hypertension and anti-coagulation therapies to prevent the recurrence of stroke are available. In Asia,
post-stroke patients with impairments are often treated with herbal medicine. The present study evaluated the eﬀectiveness of
tokishakuyakusan (TS) in improving the impairment and independence in post-stroke patients. Thirty-one post-stroke patients
(mean age=81.4 years) were recruited and enrolled. Participants were randomly assigned to the TS group (n = 16) or non-
treatment(control)group(n=15)andtreatedfor12months.ImpairmentswereassessedusingtheStrokeImpairmentAssessment
Set (SIAS). Independence was evaluated using the functional independence measure (FIM). For each outcome measure, mean
change was calculated every 3 months. The results were that impairments according to SIAS did not signiﬁcantly change in the TS
group. In contrast, SIAS signiﬁcantly worsened in the control group. There was a signiﬁcant diﬀerence between the two groups. In
each term of SIAS, aﬀected lower extremity scores, abdominal muscle strength, function of visuospatial perception, and so forth.
in the TS group were better than those in the control group. Independence according to FIM did not change signiﬁcantly in the
TS group. In contrast, FIM signiﬁcantly worsened in the control group. There was also a signiﬁcant diﬀerence between the two
groups. In conclusion, TS was considered to suppress the impairments of lower limbs and to exert a favorable eﬀect on cerebral
function for post-stroke patients.
1.Introduction
In post-stroke patients, the recurrence of stroke and pro-
gression of impairments lead to a bedridden state and
dementia. These are important medical problems in many
aging societies. However, as for their treatments, only anti-
hypertension and anti-coagulation therapies to prevent the
recurrence of stroke are available. In terms of non-drug
therapy,onlyrehabilitationisusedforinhibitingtheprogres-
sion of impairments [1, 2].
In East Asia, post-stroke patients with impairments are
often treated with herbal medicine [3], acupuncture and
moxibustion [4, 5]. Tokishakuyakusan (TS), a traditional
Chinese herbal medicine called Dang-gui-shao-yao-san in
Chinese, is reported to have a neuroendocrine eﬀect [6]a n d
to activate choline acetyltransferase [7]. Recently, the eﬃcacy
of TS on cognitive impairment from Alzheimer’s disease
[8] and improvement of microcirculation in patients with
asymptomatic cerebral infarction [9]h a v eb e e nr e p o r t e d
clinically. A neuroprotective eﬀect and the improvement of
microcirculation are thought to be useful for post-stroke
patients.Buttherehasbeennoreportonthelong-termeﬀect
of TS for post-stroke patients.
TheaimofthisstudywastodeterminewhetherTSwould
improve the impairments and independence of post-stroke
patients over a 12-month period in a randomized, controlled
trial.
2. Methods
2.1. Participants. Subjects were recruited from two long-
term-care facilities located in Toyama prefecture, Japan.2 Evidence-Based Complementary and Alternative Medicine
The diagnosis of post-stroke was made on the basis of
a history of cerebral bleeding, infarction or subarachnoid
hemorrhage as well as having paralysis due to cerebral lesion.
The patients had already passed the acute phase of stroke
and had been stable for the previous year. At baseline,
each patient underwent a uniform evaluation that included
medical history, physical and neurological examination, as
well as assessment of impairments and independence.
Impairments were assessed using the Stroke Impairment
Assessment Set (SIAS), a standardized measure of stroke
impairment consisting of the subcategories of motor, tone,
sensory, range of motion, pain, trunk function, visuospatial
function, speech and unaﬀected side function, with its high
inter-rater reliability having been reported [10, 11]. Inde-
pendence status was assessed by Functional Independence
Measure (FIM), a modality now being used throughout the
world [12]. Patients with severe dementia, were bedridden,
or had neoplastic or other disease that would likely prevent
completion of this study, were excluded. As a result, 31
patients (9 men and 22 women: mean age±SD, 81.4±8.2
years) were selected. Mean post-stroke duration of all
subjects was 68.3±75.3 months. As for original disease, 23
had cerebral infarction, seven had cerebral bleeding and one
had subarachnoid hemorrhage. Their complications mainly
consisted of hypertension, diabetes and ischemic heart
disease, but they were well controlled in this study period.
Twelve of the subjects had been using anti-coagulation drugs
prior to initiation of this study. All subjects were receiving
physio- and ergotherapy.
The study design was approved by the Human Subjects
Committee, University of Toyama. All patients provided
written informed consent in accordance with ethical guide-
lines set forth in the 1975 Declaration of Helsinki.
2.2. Intervention Protocol. A 12-month randomized, con-
trolled trial was begun between October 2005 and January
2006.ParticipantswereassignedtotheTSandcontrolgroups
using a table of random numbers (Table 1).
TS, which is approved for medical use in Japan, was
purchased from Tsumura Co. Ltd (Tokyo, Japan). It consists
of six herbs: 4.0g of Alismatis Rhizoma (Alisma orientale
JUZEPCZUK), 4.0g of Paeoniae Radix (Paeonia lactiﬂora
PALLAS), 4.0g of Atractylodis Rhizoma (Atractylodes lancea
DE CANDOLLE), 4.0g of Hoelen (Poria cocos WOLF),
3.0g of Cnidii Rhizoma (Cnidium oﬃcinale MAKINO) and
3.0g of Angelicae Radix (Angelica acutiloba KITAGAWA).
The aqueous extract was lyophilized to obtain powder.
Lactose (3.5g) was added to the powder (4.0g) to make
granules (total 7.5g). Subjects were orally administered TS
at 7.5g/day, 2.5g three times daily, 30min after meals for 12
months.
2.3. Outcome Determination. T h eS I A Ss c o r e sw e r em e a -
sured by physiotherapists who did not know which subjects
were being treated with TS. The FIM scores were measured
by care workers who had no knowledge of who the TS-
treated subjects were. Every score was determined ﬁve times:
at baseline, and every 3 months up to 12 months, the
Table 1: Clinical and demographic characteristics of study partici-
pants.
Group TS group Control group
Sex (male/female) 4/12 5/10
Age, mean±SD 81.0±9.4 81.9±7.1
Duration of illness, months,
mean±SD
77.3±86.9 58.6±62.2
Disease
Cerebral infarction 11 12
Cerebral bleeding 43
Subarachnoidal hemorrhage 10
Complication
Hypertension 11 9
Diabetes mellitus 45
Ischemic heart disease 13
Anti-coagulant drugs 57
Note: All group comparisons P> .05. SD: standard deviation; TS: Tok-
ishakuyakusan.
completion of the protocol. Body weights were measured at
the same time points.
2.4. Statistical Analysis. Changes in SIAS, FIM and body
weight from baseline (mean±SD) were compared by post
hoc test with repeated measures of analysis of variance
(ANOVA). Other data from baseline to endpoint were also
compared by Wilcoxon signed-rank test with Bonferroni
correction. P< .05 was required for statistical signiﬁcance.
3. Results
3.1.CharacteristicsofParticipants. OnlyonepatientintheTS
groupwithdrewat6weeksintothetrialbecauseofnumbness
in his limbs; besides TS, he had been taking amantadine
hydrochloride and captopril from a few weeks prior to the
start of the trial. As a result, 30 patients completed the
protocol. Participants were predominantly female. There
were no signiﬁcant diﬀerences in baseline characteristics
between the TS and control groups in terms of age, sex, post-
stroke interval, original disease or complications. Subjects
had a mean SIAS score of 44.3±18.1, a mean FIM score of
64.6±25.6, and a mean body weight of 43.3±7.5kg. There
were no signiﬁcant diﬀerences in baseline scores and body
weights between the TS and control groups (Table 2).
3.2. Changes in SIAS and Each Item. The mean SIAS score
in the TS group did not change through the 12-month
trial duration, whereas that in the control group worsened
signiﬁcantly (P< .05), the diﬀerencebetween the twogroups
being signiﬁcant (P< .05). At any of the 3-month terms of
SIAS, the next scores were signiﬁcantly diﬀerent between
the two groups. The aﬀected lower extremity scores, which
were the knee-extension test and the foot-pat test, did
not change from the beginning to 12 months in the TS
group, but they decreased signiﬁcantly in the control groupEvidence-Based Complementary and Alternative Medicine 3
Table 2: Changes in SIAS, FIM and body weight of TS and control groups.
Outcome Range Group Baseline 3 months 6 months 9 months 12 months P-valuea
SIAS 0–76 TS 43.6±20.6 45.0±21.5 43.6±20.6 43.6±20.7 43.4±20.5 .044
Control 43.6±15.9 43.3±15.6 41.9±14.9 41.2±14.7 36.9±16.6∗
FIM 0–126 TS 66.1±29.3 65.5±31.0 66.3±30.6 65.4±31.3 66.2±31.5 .008
Control 60.8±21.4 58.3±21.4 56.7±20.9 55.8±20.8 49.2±20.7∗
Body weight (kg) TS 41.6±7.1 41.7±7.8 41.8±7.4 40.5±7.3 40.1±7.4∗
.64
Control 44.6±7.8 44.3±7.9 43.9±7.6 42.6±7.7 41.9±7.4∗∗
aComparison of 12-month changes between TS group and control group.
∗P< .05, ∗∗P< .01, comparison from baseline to 12 months in the same group.
Table 3: Comparison between TS and control groups on each item of SIAS.
Variable Range TS group Control group P-valuea
Baseline 12 months Baseline 12 months
Knee-mouse 0–5 2.53±1.92 2.40±0.51 2.13±1.77 1.73±1.75∗ .295
Finger-function 0–5 2.33±1.76 2.27±1.87 1.87±1.55 1.40±1.35∗ .197
Hip-function 0–5 2.40±1.50 2.27±1.58 2.33±1.40 1.80±1.37∗∗ .262
Knee-extension 0–5 2.27 ±1.44 2.27±1.39 2.13±1.46 1.40±1.12∗∗ <.001
Foot-pat 0–5 2.33±1.45 2.27±1.39 2.27±1.67 1.73±1.44∗∗ .018
DTR 0–3 1.83±0.98 1.90±0.87 2.10±0.81 2.00±0.78 .106
Tone 0–3 2.10±1.04 1.83±1.10 2.10±0.81 2.00±0.80 .670
Touch 0–3 2.30±0.75 2.13±0.74 2.17±0.77 1.83±0.92 .237
Position 0–3 1.87 ±1.06 1.87±1.13 1.97±0.90 1.77±0.98 .219
Range of motion 0–3 1.87±1.06 1.87±1.13 1.97±0.90 1.76±0.98 .219
Pain 0–3 2.53±0.64 2.47±0.64 2.73±0.46 2.73±0.46 .560
Abdominal MMT 0–3 1.40±1.06 1.67±1.18∗ 1.33±0.82 1.20±0.86 .004
Verticality 0–3 2.27±0.80 2.13±0.99 2.07±0.59 1.73±0.88∗ .359
Visuo-spat. score 0–3 1.67±1.35 1.80±1.42 1.67±0.98 1.33±1.18∗ .031
Speech 0–3 2.00±0.93 1.87±0.92 1.73±0.70 1.40±0.74 .681
Unaﬀected quadriceps 0–3 1.80±0.78 1.87±0.74 1.93±0.70 1.53±0.83∗ .022
Unaﬀected grip power (kg) 8.93±6.20 8.07±6.31 10.7±7.16 8.80±7.67 .671
DTR, deep tender reﬂexes; MMT, manual muscle testing; Visuo-spat., visuospatial perception.
aComparison of 12-month changes between TS group and control group.
∗P< .05, ∗∗P< .01, Comparison between baseline and at 12 months in the same group.
(P< .01). Abdominal muscle strength, a measure of the
function of the trunk of the body, improved from the
beginning to 12 months in the TS group (P< .05) but it
did not change in the control group during the 12 months.
The function of visuospatial perception did not change
from the beginning to 12 months in the TS group, but it
decreased signiﬁcantly in the control group (P< .05). The
muscle strength of unaﬀected quadriceps, important for
maintaining the activity of daily living, did not change in the
TS group, but it decreased signiﬁcantly in the control group
(P< .05) (Table 3).
3.3. Changes in FIM and Body Weight. The mean FIM score
in the TS group did not change during the 12 months,
whereas that in the control group worsened signiﬁcantly
(P< .05), the diﬀerence between the two groups being signi-
ﬁcant (P< .01). The body weights of both groups decreased
signiﬁcantly during the 12 months, but there were no
signiﬁcant diﬀerences between the two groups (Table 2). In
the control group, two subjects had recurrent stroke between
9 and 12 months.
4. Discussion
During the long-term period of 12 months, despite the lim-
itation of the small study population, this preliminary and
randomized trial suggested that TS inhibited the worsening
of impairments and independence in post-stroke patients.
As for the method of stroke impairment assessment, several
kinds have been developed, such as the Canadian Neuro-
logical Scale [13] and NIH Scale [14]. SIAS, used in this
study,istheassessmentbasedontheguidelinesoftheBuﬀalo
Symposium of 1989 [15], and has recently been often used
clinically to assess the impairment in post-stroke patients
in Japan, as it can assess not only motor functions but also
sensory functions and range of motion at the joints [11].4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Hypothetical representation of the eﬀects of TS on post-stroke patents. LH-RH: luteum hormone releasing hormone; PRL:
prolactin; Ach-R: acetylcholine receptor; ChAT: choline acetyltransferase; NGF: nerve growth factor.
The maximum score on SIAS is 76 points, and partic-
ipants with SIAS scores around 40 points do not have not
completeparalysis,buttheydohaveparesisinaﬀectedlimbs.
Independence was evaluated using FIM, a measurement in
use worldwide [12]. The maximum score on FIM is 126
points, and participants with FIM scores around 60 points
have a physical state needing slight to middle-level care.
Aged participants who have had paresis for 5 or 6 years
will show slowly worsening impairments and independence.
With the recurrence of stroke, their condition will worsen
precipitously.
Recently, by reason of being unable to live alone, many
post-stroke patients, whose impairments are of mild or
mediumgrade,arelivinginlong-termcarefacilitiesinJapan.
In this respect then, participants in this study are not rare
cases, and their impairments advance step by step, ﬁnally
leading to a bedridden state. As this is now a severe medical
probleminJapan,anymethod oftreatmentthatcanimprove
this situation would be more than welcome. There are a
few reports concerning the study of the eﬀects of traditional
Chinese medicine in post-stroke patients. The eﬀects on
aspiration pneumonia [16] and cognitive function [17, 18]
of post-stroke patients for the short term were reported. Of
course, maintaining function and ability, and prolonging the
period of social life are also of major importance. In this
regard, TS is one of the most common formulas in oriental
traditional medicine and has been used in large numbers
of patients for 2000 years. The administration and safety
of TS have been clinically established. It is often used for
gynecological diseases [19, 20]. There are some reports on
climacteric symptoms [21] and improvement of luteal insuf-
ﬁciency [22]. These reports are interesting, as TS has been
reportedtoimprovememorydisturbanceinmenopausalrats
[7]. In addition, TS is used for dermatological diseases [23]
as well as many other medical conditions [24].
Recently there have been some reports about the treat-
ment of patients with cognitive diﬃculties with Kampo
medicine, as for example, the eﬀect of kihito and BaWei Di
Huang Wan on cognitive function [25, 26], and the eﬀect of
Yi-Gan San on psychiatric symptoms and sleep structure in
dementia patients [27]. But the mechanisms of the functions
of these formulas are not yet suﬃciently clear. In this study,
TS was eﬀective in suppressing impairments of lower limbs
and in favorably inﬂuencing visuospatial perception. But
there are few reports regarding the improvement of muscle
strength and paralysis in neurological diseases treated with
TS. The mechanisms of these eﬀects are thought to be related
to activation of brain function, to have a suppressive eﬀect
against re-stroke, and to ameliorate weakness in muscle
strength. There are also some reports on TS and the central
nervous system. The synthesis and release of neurotrans-
mitters such as acetylcholine, dopamine and norepinephrine
have been reported before [6, 7]. Recently, in terms of
neuroprotection, the protective eﬀect against amyloid β-
induced neuronal damage [28] and that after peripheral
facial nerve axotomy [29] have been reported. Further, con-
cerningbloodcirculation,antioxidantandantiplateleteﬀects
[30] and regulation of genes associated with thrombosis
[31] have been reported. Clinically, TS has been studied
in terms of its eﬃcacy against Alzheimer-type dementia
[32], and recently its eﬀect on mild cognitive impairment
was reported [8]. Furthermore, we previously demonstrated
that TS improved the microcirculation in patients with
asymptomatic cerebral infarction. Its mechanisms were
believedtoimprovethehemorheologicalfeaturesofviscosity
and erythrocyte deformability and to decrease plasma lipid
peroxides [9]. Such favorable eﬀects, which protect neurons
and improve cerebral blood circulation, would suppress
the worsening of impairments and independence in post-
stroke patients. Furthermore, as shown by the improvement
of visuospatial perception, TS aﬀected cerebral function,
especially the parietal lobe [33]. Another Kampo formula,
Chotosan, was also reported to have some activity in frontal
lobe function [34]. A hypothetical representation of the
eﬀects of TS on post-stroke patients is summarized in
Figure 1.
In the present study, subjects were separated into two
groups randomly, and they were assessed using SIAS andEvidence-Based Complementary and Alternative Medicine 5
FIM to easily study impairment and independence. The
measurements of SIAS and FIM were used to represent as
objective an assessment as possible. The SIAS scores were
measured by physiotherapists who were unaware of which
subjects were being treated with TS. The FIM scores were
measured by similarly blinded care workers. But without the
use of placebo, the need for a blind cohort was obviously not
satisﬁed. Although placebo is hard to use in a long-term trial
such as the present 1-year term, a well-controlled trial of TS
with a larger sample size and the use of comparison drugs
will be needed in the future.
Ineveryagingsociety,keepingtheincreasingpopulations
of bed-ridden post-stroke patients to a minimum is of
major importance, making the ﬁndings of this preliminary
study, demonstrating that TS could slow deteriorations
in impairment and independence in post-stroke subjects,
particularly interesting.
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